Pi Health is a technology company.
Pi Health has raised $31.0M across 1 funding round.
Pi Health has raised $31.0M in total across 1 funding round.
Pi Health has raised $31.0M in total across 1 funding round.
Pi Health's investors include AlleyCorp, Alumni Ventures, Fika Ventures, FPV Fund, General Catalyst, Greycroft, Homebrew, Jazz Venture Partners, Kavita Patel, Northzone, Obvious Ventures, Cherian Mathew.
Pi Health is an AI-powered clinical research organization (CRO) focused on oncology trials, building the FICS platform to streamline drug development, connect sponsors and global sites, and expand access to innovative medicines for diverse patient populations.[1][2][4] It serves life science companies, oncology centers, and patients by solving inefficiencies in clinical trials—such as fragmented data collection, slow enrollment, and limited global reach—through unified technology, expert operations, and a worldwide site network spanning the US, Brazil, Australia, and India.[1][2][5] With $30M+ in Series A funding announced in March 2024 (totaling nearly $40M), Pi Health demonstrates strong growth momentum, including the 2023 launch of its research-focused Pi Health Cancer Hospital in Hyderabad, India, and recent additions like an AI-powered study startup platform.[1][5]
Pi Health emerged from the experiences of physician-founders Shiva Reddy and John Kim, who identified critical gaps in oncology clinical trials while working in clinical practice, regulatory science, and industry roles—Reddy at AstraZeneca heading oncology regulatory science and innovation, and Kim as VP of oncology strategic combinations.[5] Incubated as a wholly owned subsidiary of BeiGene for four years, it launched independently in 2021 (with some sources noting 2023 incorporation) from Cambridge, Massachusetts, backed by venture funding led by Obvious Ventures and AlleyCorp.[1][3][5] Pivotal early traction included forging health system partnerships across four continents and opening the Pi Health Cancer Hospital in Hyderabad in December 2023, which uses FICS for real-world data capture and trial recruitment, proving the model's viability for underserved populations.[1][5]
Pi Health stands out in the clinical trial management systems market (where it's positioned as a Challenger alongside Oracle and Veeva) through its integrated, AI-native approach combining technology, operations, and global infrastructure:[3][4]
Pi Health rides the wave of AI-native clinical development 2.0, addressing a $31B+ North American clinical trial software market (projected to $50B by 2033) strained by inefficiencies, regulatory demands, and the need for diverse, global patient access in oncology—where North America dominates but Asia-Pacific grows fastest.[3] Timing is ideal amid rising R&D in pharma/CROs/CDMOs, post-pandemic decentralization trends, and AI's role in streamlining trials (e.g., reducing reliance on third-party services).[2][3][4] It influences the ecosystem by proving scalable models for equitable trials in emerging markets like India, empowering non-academic sites, and setting benchmarks for integrated platforms that accelerate breakthroughs while improving data integrity and compliance.[1][5]
Pi Health is poised to scale its global network and FICS enhancements—like the new AI study startup platform—targeting further cost reductions and faster trial timelines amid booming oncology R&D and AI adoption in clinical research.[5] Trends like regulatory emphasis on real-world evidence, inclusive enrollment, and Asia-Pacific expansion will propel it, potentially capturing more market share from incumbents through its physician-led, vertically integrated edge. As it evolves from startup to category leader, Pi Health could redefine equitable access to innovative medicines, transforming how lifesaving therapies reach global patients faster.
Pi Health has raised $31.0M across 1 funding round. Most recently, it raised $31.0M Series A in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $31.0M Series A | AlleyCorp, Alumni Ventures, Fika Ventures, FPV Fund, General Catalyst, Greycroft, Homebrew, Jazz Venture Partners, Kavita Patel, Northzone, Obvious Ventures, Cherian Mathew, Gokul Rajaram |